Main Article Content

Abstract

Helicteres Isora root is a well-known antidiabetic medicinal plant used for several traditional medicine aspects in different areas of the world, including India. This study includes phytochemical analysis, antidiabetic evaluation. The root of Helicteres Isora has been used in traditional health systems to treat diabetes mellitus in India. However, the antidiabetic activity of this medicinal plant is not scientifically validated and authenticated. The present study aimed to investigate the in vitro and in vivo anti-diabetic activity of root crude extract and solvent fractions of Helicteres Isora.  The aim of this study was to investigate the antidiabetic activity and mechanism of action of Ethanolic extract prepared from Helicteres Isora root. Since this claim has not been investigated scientifically, the aim of this study was to evaluate the antidiabetic effect and phytochemical screening of Streptozotocin -induced diabetic Rats. The result demonstrated the beneficial biochemical effects of Helicteres Isora root extract by inhibiting α–amylase improving serum lipid profile levels. The root crude extract are effective in lowering blood glucose levels in diabetic and hypoglycemic rats. The claimed traditional use as antidiabetic has scientific ground.

Keywords

Diabetes mellitus Herbal medicine Helicteres Isora root Streptozotocin Anti diabetic activity

Article Details

How to Cite
Prathikantam Madhushalini, D. Swathi, K. Chaitanyaprasad, & K. Shravankumar. (2025). In Vivo Anti Diabetic Activity Of Helicteres Isora On Streptozotocin-Induced Diabetic In Rats. International Journal of Research in Pharmacology & Pharmacotherapeutics, 14(1), 57-66. Retrieved from https://ijrpp.com/ijrpp/article/view/616

References

  1. 1. Consultation, W. H. O. Definition, diagnosis and classification of diabetes mellitus and its complications. Vol. 1. Part, 1999.
  2. 2. Alberti, Kurt George Matthew Mayer, and PZ ft Zimmet. "Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation." Diabetic medicine 15.7 (1998): 539-553.
  3. 3. Gress, Todd W., et al. "Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus." New England Journal of Medicine 342.13 (2000): 905-912.
  4. 4. Ahmed, Awad M. "History of diabetes mellitus." Saudi medical journal 23.4 (2002): 373-378.
  5. 5. Zimmet, Paul Z., Daniel J. McCarty, and Maximilian P. de Courten. "The global epidemiology of non-insulin-dependent diabetes mellitus and the metabolic syndrome." Journal of Diabetes and its Complications 11.2 (1997): 60-68.
  6. 6. American Diabetes Association. "Type 2 diabetes in children and adolescents."Pediatrics 105.3 (2000): 671-680.
  7. 7. Saltiel, Alan R., and C. Ronald Kahn. "Insulin signalling and the regulation of glucose and lipid metabolism." Nature 414.6865 (2001): 799-806.
  8. 8. Browning, Jeffrey D., and Jay D. Horton. "Molecular mediators of hepatic steatosis and liver injury." Journal of Clinical Investigation 114.2 (2004): 147-152.
  9. 9. Aronoff, Stephen L., et al. "Glucose metabolism and regulation: beyond insulin and glucagon." Diabetes Spectrum 17.3 (2004): 183-190.
  10. 10. Ross, E. J., and D. C. Linch. "Cushing's syndrome—killing disease: discriminatory value of signs and symptoms aiding early diagnosis." The Lancet320.8299 (1982): 646-649.
  11. 11. Levin, Marvin E., Vincenza C. Boisseau, and Louis V. Avioli. "Effects of diabetes mellitus on bone mass in juvenile and adult-onset diabetes." New England Journal of Medicine 294.5 (1976): 241-245.
  12. 12. Sherwin, Robert, and Philip Felig. "Pathophysiology of diabetes mellitus." The Medical clinics of North America 62.4 (1978): 695-711.
  13. 13. Faber, O. K., and C. Binder. "C-peptide response to glucagon: a test for the residual β-cell function in diabetes mellitus." Diabetes 26.7 (1977): 605-610.
  14. 14. Ioannidis, Ioannis. "Pathophysiology of Type 1 diabetes." Diabetes in Clinical Practice: Questions and Answers from Case Studies 31 (2007): 23.
  15. 15. Scheen, A. J. "Pathophysiology of type 2 diabetes." Acta Clinica Belgica 58.6 (2003): 335-341.